Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 364

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 364
---
 36 months, or vests on the six-monthanniversary of the consummation of the Company’s first underwritten public offering (“IPO”) under the Securities Act of 1933, as amended. A summary of the Company’s restricted stock activity is as follows:

|                                          |     | Shares         
 (in thousands) |      |   |     | Weighted   
 Average    
 Grant Date 
 Fair Value |      |
|:-----------------------------------------|:----|:---------------|-----:|:--|:----|:-----------|-----:|
| Unvested Balance at December 31, 2022    |     |                |  465 |   |     | $          | 0.46 |
| Granted                                  |     |                |   12 |   |     | $          | 0.83 |
| Vested                                   |     |                | (283 | ) |     | $          | 0.51 |
| Unvested Balance at December 31, 2023    |     |                |  194 |   |     | $          | 0.41 |
| Granted                                  |     |                |    — |   |     | $          |    — |
| Vested                                   |     |                |   (4 | ) |     | $          | 0.83 |
| Unvested balance as of December 31, 2024 |     |                |  190 |   |     | $          | 0.40 |

During the year ended December 31, 2023, the Company agreed with its Chief Medical Officer to accelerate the vesting of 0.1 million shares of restricted stock. The Company recorded $0.1 million of stock-based compensation expense within research and development in the accompanying statement of operations for the year ended December 31, 2023. As part of the Series C Offering, the Company modified certain restricted stock awards that were previously awarded to employees and non-employeesto accelerate the vesting from six months after the consummation of an IPO to immediate vesting. An aggregate amount of 0.2 million restricted stock vested upon the closing of the Series C Offering in August 2023. The Company recorded $0.1 million and less than $0.01 million of stock-based compensation with general and administrative and research and development, respectively in the accompanying statement of operations for the year ended December 31, 2023. The total fair value of restricted stock that vested